Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer

被引:33
作者
Wu, Jenn-Yu [1 ]
Shih, Jin-Yuan [2 ,3 ]
机构
[1] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Internal Med, Yunlin, Taiwan
[2] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
关键词
EGFR; erlotinib; gefitinib; lung cancer; mutations; EGFR EXON 18; PULMONARY ADENOCARCINOMA; ACQUIRED-RESISTANCE; GEFITINIB TREATMENT; ERLOTINIB; SURVIVAL; 1ST-LINE; THERAPY; RARE; CHEMOTHERAPY;
D O I
10.2147/OTT.S118071
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Clinical features of epidermal growth factor receptor (EGFR) mutations: L858R, deletions in exon 19, T790M, insertions in exon 20, G719X, and L861X in non-small-cell lung cancer (NSCLC) are well-known. The clinical significance of other uncommon EGFR mutations, such as E709X, is not well understood. This study aimed to improve the understanding of E709X, and the clinical response to tyrosine kinase inhibitors (TKIs) of NSCLC patients with such an uncommon mutation. Methods: Specimens from 3,146 patients were tested for EGFR mutations. We surveyed the clinical data and the effectiveness of TKI treatment in NSCLC patients with EGFR mutations E709X. Results: Of the 3,146 patients, 1,689 (53.7%) had EGFR mutations. This included 726 patients with deletions in exon 19, 733 patients with L858R, and 230 (13.6%) patients with other EGFR mutations. In the 230 patients who had mutations other than single deletion in exon 19 or single L858R in exon 21, 25 (1.5%) patients had the uncommon E709X mutations. Twenty patients had complex E709X mutations and five had single E709X mutation: delE709-T710insD. Of these 25 patients, 18 received either gefitinib or erlotinib treatment. The response rate of TKIs treatment was 50.0%, and the median progression-free survival was 6.2 months. All 5 patients who had delE709-T710insD were non-responders to TKI treatments. Conclusion: E709X EGFR mutations constituted a small part of the whole group of EGFR mutations. Most patients had complex mutations. The mutation delE709-T710insD was a single mutation and was not associated with good response to TKI treatment.
引用
收藏
页码:6137 / 6145
页数:9
相关论文
共 38 条
[1]   EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non-Small-Cell Lung Cancer [J].
Ackerman, Allison ;
Goldstein, Michael A. ;
Kobayashi, Susumu ;
Costa, Daniel B. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) :E19-E20
[2]   Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].
Balak, Marissa N. ;
Gong, Yixuan ;
Riely, Gregory J. ;
Somwar, Romel ;
Li, Allan R. ;
Zakowski, Maureen F. ;
Chiang, Anne ;
Yang, Guangli ;
Ouerfelli, Ouathek ;
Kris, Mark G. ;
Ladanyi, Marc ;
Miller, Vincent A. ;
Pao, William .
CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501
[3]   Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network [J].
Beau-Faller, M. ;
Prim, N. ;
Ruppert, A. -M. ;
Nanni-Metellus, I. ;
Lacave, R. ;
Lacroix, L. ;
Escande, F. ;
Lizard, S. ;
Pretet, J. -L ;
Rouquette, I. ;
de Cremoux, P. ;
Solassol, J. ;
de Fraipont, F. ;
Bieche, I. ;
Cayre, A. ;
Favre-Guillevin, E. ;
Tomasini, P. ;
Wislez, M. ;
Besse, B. ;
Legrain, M. ;
Voegeli, A. -C. ;
Baudrin, L. ;
Morin, F. ;
Zalcman, G. ;
Quoix, E. ;
Blons, H. ;
Cadranel, J. .
ANNALS OF ONCOLOGY, 2014, 25 (01) :126-131
[4]   Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy [J].
Chan, SK ;
Gullick, WJ ;
Hill, ME .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (01) :17-23
[5]   EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations:: one-third of doublets occur at five pairs of amino acids [J].
Chen, Z. ;
Feng, J. ;
Saldivar, J-S ;
Gu, D. ;
Bockholt, A. ;
Sommer, S. S. .
ONCOGENE, 2008, 27 (31) :4336-4343
[6]   EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis [J].
Cheng, Chao ;
Wang, Rui ;
Li, Yuan ;
Pan, Yunjian ;
Zhang, Yang ;
Li, Hang ;
Zheng, Difan ;
Zheng, Shanbo ;
Shen, Xuxia ;
Sun, Yihua ;
Chen, Haiquan .
SCIENTIFIC REPORTS, 2015, 5
[7]   Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations [J].
De Pas, Tommaso ;
Toffalorio, Francesca ;
Manzotti, Michela ;
Fumagalli, Caterina ;
Spitaleri, Gianluca ;
Catania, Chiara ;
Delmonte, Angelo ;
Giovannini, Monica ;
Spaggiari, Lorenzo ;
de Braud, Filippo ;
Barberis, Massimo .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) :1895-1901
[8]   Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants [J].
Greulich, H ;
Chen, TH ;
Feng, W ;
Jänne, PA ;
Alvarez, JV ;
Zappaterra, M ;
Bulmer, SE ;
Frank, DA ;
Hahn, WC ;
Sellers, WR ;
Meyerson, M .
PLOS MEDICINE, 2005, 2 (11) :1167-1176
[9]   Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature [J].
Gu, Dongqing ;
Scaringe, William A. ;
Li, Kai ;
Saldivar, Juan-Sebastian ;
Hill, Kathleen A. ;
Chen, Zhenbin ;
Gonzalez, Kelly D. ;
Sommer, Steve S. .
HUMAN MUTATION, 2007, 28 (08) :760-770
[10]   Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib [J].
Han, SW ;
Kim, TY ;
Hwang, PG ;
Jeong, S ;
Kim, J ;
Choi, IS ;
Oh, DY ;
Kim, LH ;
Kim, DW ;
Chung, DH ;
Im, SA ;
Kim, YT ;
Lee, JS ;
Heo, DS ;
Bang, YJ ;
Kim, NK .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2493-2501